

Special Issue

Personalized Medicine of Cognitive Impairments Associated with Psychiatric Disorders

Message from the Guest Editor

Patients with psychosis show impairment over a broad spectrum of the cognitive domain, with deficits in attention, memory, executive function, and social cognition. Moreover, cognitive functioning is a predictor of social functioning, which includes such aspects as the ability to carry out activities of daily living, level of work functioning, and quality of interpersonal relations. Cognitive impairments also lead to difficulties for patients and families with nonpsychotic disorders. The clinical symptoms that define a disease are often linked to different pathophysiological processes that may not be immediately obvious in the clinical setting, making the optimal treatment for an individual patient uncertain and leading to a suboptimal trial-and-error treatment process. Understanding the underlying biology of disease and individual patient variation may improve care for patients, leading to more optimal outcomes. Both pharmacotherapy and psychological intervention are currently the main treatments for such cognitive impairments, and this special issue welcomes the latest research on pharmacotherapy and psychological intervention for all psychiatric disorders.

Guest Editor

Prof. Dr. Takahiro Nemoto
Department of Neuropsychiatry, Toho University Faculty of Medicine,
Tokyo, Japan

Deadline for manuscript submissions

closed (15 March 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/142161

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).